SI3592355T1 - KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze - Google Patents

KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze

Info

Publication number
SI3592355T1
SI3592355T1 SI201831294T SI201831294T SI3592355T1 SI 3592355 T1 SI3592355 T1 SI 3592355T1 SI 201831294 T SI201831294 T SI 201831294T SI 201831294 T SI201831294 T SI 201831294T SI 3592355 T1 SI3592355 T1 SI 3592355T1
Authority
SI
Slovenia
Prior art keywords
treatment
actinic keratosis
keratosis
actinic
Prior art date
Application number
SI201831294T
Other languages
English (en)
Slovenian (sl)
Inventor
Min-Fun Rudolf Kwan
Johnson Yiu-Nam Lau
E. Douglas Kramer
David Lawrence Cutler
Jane Fang
Original Assignee
Atnx Spv, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3592355(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv, Llc filed Critical Atnx Spv, Llc
Publication of SI3592355T1 publication Critical patent/SI3592355T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201831294T 2017-03-10 2018-03-12 KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze SI3592355T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
EP18764980.1A EP3592355B1 (en) 2017-03-10 2018-03-12 Kx2-391/kx-01 for use in the treatment of actinic keratosis
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (1)

Publication Number Publication Date
SI3592355T1 true SI3592355T1 (sl) 2026-04-30

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201831294T SI3592355T1 (sl) 2017-03-10 2018-03-12 KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze

Country Status (23)

Country Link
US (3) US10617693B2 (https=)
EP (2) EP3592355B1 (https=)
JP (3) JP7502863B2 (https=)
KR (2) KR20240090837A (https=)
CN (1) CN110891575A (https=)
AU (2) AU2018231144B2 (https=)
BR (1) BR112019018687A2 (https=)
CA (1) CA3055938A1 (https=)
DK (1) DK3592355T3 (https=)
ES (1) ES3060528T3 (https=)
FI (1) FI3592355T3 (https=)
HR (1) HRP20260155T1 (https=)
IL (1) IL269182B2 (https=)
LT (1) LT3592355T (https=)
MX (2) MX387658B (https=)
NZ (1) NZ757105A (https=)
PL (1) PL3592355T3 (https=)
PT (1) PT3592355T (https=)
RS (1) RS67713B1 (https=)
SI (1) SI3592355T1 (https=)
TW (1) TWI841523B (https=)
WO (1) WO2018165647A1 (https=)
ZA (1) ZA202100106B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN117599189A (zh) * 2018-03-07 2024-02-27 慧源Spv公司 用于治疗过度增殖性皮肤障碍的组合物和方法
JP7296945B2 (ja) * 2018-03-28 2023-06-23 テルモ株式会社 医療デバイス
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
JP2024506240A (ja) * 2021-01-21 2024-02-13 サーナオミクス インコーポレイテッド 皮膚がんの治療のための組成物および方法
WO2025077886A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
WO2008144045A1 (en) 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
SI2378876T1 (sl) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
KR20190141661A (ko) 2019-12-24
DK3592355T3 (da) 2026-02-16
IL269182B2 (en) 2023-11-01
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
KR20240090837A (ko) 2024-06-21
AU2018231144B2 (en) 2023-12-21
JP2023015269A (ja) 2023-01-31
AU2024201828A1 (en) 2024-05-02
LT3592355T (lt) 2026-02-25
JP2025029010A (ja) 2025-03-05
US20180256589A1 (en) 2018-09-13
JP2020510042A (ja) 2020-04-02
HRP20260155T1 (hr) 2026-03-27
PT3592355T (pt) 2026-02-03
RU2019131757A3 (https=) 2021-05-31
TWI841523B (zh) 2024-05-11
EP4659740A3 (en) 2026-02-18
EP3592355A1 (en) 2020-01-15
US11497750B2 (en) 2022-11-15
TW201842913A (zh) 2018-12-16
US10617693B2 (en) 2020-04-14
EP3592355B1 (en) 2025-12-10
NZ757105A (en) 2026-02-27
RS67713B1 (sr) 2026-02-27
AU2024201828B2 (en) 2026-02-19
US20230172942A1 (en) 2023-06-08
BR112019018687A2 (pt) 2020-04-07
EP4659740A2 (en) 2025-12-10
WO2018165647A1 (en) 2018-09-13
MX2019010707A (es) 2020-01-15
FI3592355T3 (fi) 2026-02-13
AU2018231144A1 (en) 2019-10-03
ZA202100106B (en) 2022-08-31
IL269182A (en) 2019-11-28
EP3592355A4 (en) 2021-01-06
RU2019131757A (ru) 2021-04-12
MX387658B (es) 2025-03-18
JP7502863B2 (ja) 2024-06-19
IL269182B1 (en) 2023-07-01
PL3592355T3 (pl) 2026-04-07
CA3055938A1 (en) 2018-09-13
ES3060528T3 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
GB201614522D0 (en) Use of cannabinoids in the treatment of multiple myeloma
SMT202500241T1 (it) Elafibranor per uso nel trattamento di colangite biliare primitiva
SI3592355T1 (sl) KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze
SMT202100468T1 (it) 24-idrossisteroli sostituiti in posizione 11 per l'uso nel trattamento delle condizioni correlate all'nmda
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
PT3331610T (pt) Agentes para utilização no tratamento de glioma
GB2553527B (en) Headgear suitable for use in hydrotherapy
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL269121A (en) Usl-311 for use in the treatment of cancer
LT3548006T (lt) Kompozicija, skirta žarnyno pakitimams gydyti
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
IL257342A (en) Lisobactin for use in the treatment of udder inflammation in cattle
IL255291A0 (en) Using potassium hydroxide to treat actinic keratosis
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases